Close Menu

thyroid cancer

The randomized, 400-patient trial will compare selpercatinib to chemotherapy for first-line treatment of medullary thyroid cancer.

The firms plan to use Thermo Fisher's Oncomine Dx Target test to identify cancer patients with RET alterations who might benefit from Lilly's LOXO-292.

The groups will use Helomics' artificial intelligence-based platform to develop tools to provide predictive therapeutic recommendations for ovarian and thyroid cancers.